SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.51-1.3%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sidney Street who wrote (10841)3/4/2004 10:21:38 PM
From: IRWIN JAMES FRANKEL  Read Replies (2) of 52153
 
Hi Sidney,

The beta-interferons used to treat MS, ordered by increasing strength are Avonex, Betaseron and Rebif. As dosage strength increases so does the development of antibodies to beta-interferon. Also as the dosage increases the time to anti-body resistance shortens. This is a vicious cycle of reduced effectiveness leading to the increased dose and accelerated production of anti-bodies. So there is a big and growing market for a better treatment. That may be one reason for FDA's response to Antegren.

Copaxone is not subject to this anti-body problem but it does require daily shots compared to less frequent Ifn shots.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News